A combination of cabozantinib and atezolizumab improved the PFS in patients with Advanced HCC
Kristie Rosa
Advertisement
Articles by Kristie Rosa
Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen), has been launched in the United States at a significant discount. The shipment of the biosimilar to wholesalers throughout the United States began on Nov. 12, 2018.
Advertisement
Latest Updated Articles
Epoetin Alfa Biosimilar Launched at Significant Discount in USNovember 21st 2018
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI and Oncology Nursing: Detecting Misdiagnosis With Molecular Profiling
2
FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer: What Nurses Need to Know
3
FDA Approves First On-Body Injector for Multiple Myeloma Treatment
4
FDA Approves Gedatolisib for HR+/HER2- Metastatic Breast Cancer
5